NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover's "Top 10 Cardiovascular/Metabolic Projects to Watch." Along with inclusion in the "Top 10 to Watch" list, NormOxys is making a presentation today at Windhover's Therapeutic Area Partnerships meeting, which is being held at the Westin Copley Place in Boston.

“We believe that oxyrens have the potential to revolutionize the treatment of a number of disorders by delivering significant clinical benefit to patients, and we look forward to continuing with our clinical progress to evaluate the efficacy of OXY111A in chronic heart failure and cancer.”

OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin, was selected for inclusion in this prestigious list by a committee that included independent experts in cardiovascular and metabolic diseases as well as representatives from Windhover Information, the publishers of IN VIVO and Start-Up.

Currently in Phase 1 human clinical testing, OXY111A has shown in preclinical studies that it enhances oxygen delivery to hypoxic tissues. The ability of OXY111A to affect an increased, regulated delivery of oxygen to hypoxic tissue provides a mechanism for delivery of oxygen to organs and cells in chronic heart failure, and to normalize the oxygen tension in cancer cells in order to inhibit the growth and metastasis of several types of tumors. OXY111A is NormOxys' lead drug candidate from its pipeline of novel small molecule drugs, oxyrens, which have potential to be developed in a broad range of clinical indications, where therapeutic benefit can be obtained by enhancing the body's ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency.

"We are delighted and honored that respected industry experts have recognized the breakthrough therapeutic potential of NormOxys' oxyrens and in particular our lead clinical candidate, OXY111A," said Martin Tolar, M.D., Ph.D., chief executive officer of NormOxys. "We believe that oxyrens have the potential to revolutionize the treatment of a number of disorders by delivering significant clinical benefit to patients, and we look forward to continuing with our clinical progress to evaluate the efficacy of OXY111A in chronic heart failure and cancer."

"Selected companies have been screened using a strict set of judging criteria for the Top 10 Award and represent what our committees considered the most attractive cardiovascular and metabolic opportunities the industry has to offer," said David Cassak, Vice President of Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."